BIIB would fit right into the bio-pharma business model of BMY, which can certainly pull it off once it spins off Mead Johnson.
I got a question though, it's not clear that BIIB has right to take Tysabri away from ELN without putting up a huge chunk of dough. Either way, this should help pay off the 1 billion plus debt. If that is gone, what should ELN be valued at. I'd say 5 billion dollars on Tysabri alone.
Market Data 
Markets 
AI
